Dynavax (Group)

https://www.dynavax.com

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent allergies, infectious diseases, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our pipeline includes: TOLAMBA(TM), a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV(TM), a hepatitis B vaccine in Phase 3; a therapy for non-Hodgkin's lymphoma in Phase 2 and a therapy for metastatic colorectal cancer in Phase 1. Our pre-clinical asthma and COPD programs are partnered with AstraZeneca. Funding for our colorectal cancer program and our preclinical programs in hepatitis B and hepatitis C therapies and for an influenza vaccine has been provided by Symphony Dynamo, Inc. and the NIH, and these programs represent future partnering opportunities. *

	Start	1996-08-01 established
	Today	Dynavax Technologies Corporation (Nasdaq: DVAX)
	Industry	pharmaceutical
	Industry 2	vaccine

	Region	Berkeley, CA
	Country	United States (USA)
	Street	2929 Seventh Street Suite 100
	City	94710 Berkeley, CA
	Tel	+1-510-848-5100
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	14,655,000 (revenues, total, consolidated (2005) 2005-12-31)
	Profit	-20,555,000 (2005-12-31)
	Cash	75,110,000 (2005-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Dynavax (Group)

[1] Valneva S.E.. (4/22/20). "Press Release: Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19". Saint-Herblain & Emeryville, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]